(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose ...
Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Eli Lilly now expects 2024 revenue of $42.4 billion to $43.6 billion, up from its previous forecast of $40.4 billion to $41.6 billion. The drugmaker also raised its annual profit forecast by $1.30 ...
Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...
Analysts had expected sales of $2.08 billion. Eli Lilly raised its annual profit forecast by $1.30 per share to a range of $13.50 to $14 per share. The drugmaker also bumped its annual forecast by $2 ...
said CEO David Ricks. Eli Lilly & Co. (LLY) posted stronger-than-expected fourth quarter earnings Thursday, while lifting its full-year profit forecast, as sales of its blockbuster diabetes ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Soaring sales of Eli Lilly’s hugely popular diabetes and weight loss drugs Mounjaro and Zepbound prompted ...
※ニュースには当該企業と関連のない記事が含まれている場合があります。 医薬品の開発・製造を手掛け、約105カ国で販売 ...
Soaring sales of Eli Lilly’s hugely popular diabetes and weight-loss drugs Mounjaro and Zepbound prompted the US pharmaceutical group to lift its guidance for the year and pushed its share price ...